We therefore anticipated that degludec would have greater benefits in patients particularly prone to hypoglycemia, and our results show that not only is the risk of hypoglycemia reduced in such patients, but there is also an improvement in glycemic control without an increase in insulin dose for the majority of patients. This evidence concerns the gene INS and Hypoglycemia.